Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 6/20 | 0.69 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7080884 | 1.00 | AR (0.69) | ARSRD5A2KCNH2 | |
| SCHEMBL5214729 | 0.93 | AR (0.62) | ARSRD5A2KCNH2 | |
| SCHEMBL5215924 | 0.92 | AR (0.63) | ARSRD5A2KCNH2 | |
| SCHEMBL5210847 | 0.92 | AR (0.63) | ARSRD5A2KCNH2 | |
| SCHEMBL5218071 | 0.91 | AR (0.58) | ARSRD5A2 | |
| SCHEMBL5250126 | 0.91 | AR (0.67) | ARSRD5A2KCNH2 | |
| SCHEMBL5211932 | 0.91 | AR (0.67) | ARSRD5A2KCNH2 | |
| SCHEMBL7077337 | 0.91 | AR (0.58) | ARSRD5A2 | |
| SCHEMBL5211037 | 0.91 | AR (0.62) | ARSRD5A2KCNH2 | |
| SCHEMBL7077749 | 0.91 | AR (0.62) | ARSRD5A2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1420796-A4 | ANDROGEN RECEPTOR MODULATORS AND METHODS OF USE THEREOF | MERCK & CO INC (US) | 2007-07-11 | — | — | EP | claimed |
| EP-1420796-A1 | ANDROGEN RECEPTOR MODULATORS AND METHODS OF USE THEREOF | Merck & Co., Inc. (US) | 2004-05-26 | — | — | EP | claimed |
| US-6645974-B2 | Administering an androstamide compound; osteoporosis, anticancer agents, glandular disorders | MERCK & CO., INC. | 2003-11-11 | — | — | US | claimed |
| US-20030065004-A1 | Androgen receptor modulators and methods for use thereof | MERCK SHARP & DOHME CORP. | 2003-04-03 | — | — | US | claimed |
| WO-2003011302-A1 | ANDROGEN RECEPTOR MODULATORS AND METHODS OF USE THEREOF | MERCK & CO., INC. (US) | 2003-02-13 | — | — | WO | claimed |
| EP-0547691-B1 | The use of 17B-N-mono-substituted-carbamoyl-4-aza-5alpha-androst-1-en-3-ones for the preparation of a medicament for the prevention of prostatic carcinoma | MERCK & CO INC (US) | 1997-03-19 | — | — | EP | claimed |
| EP-1420796-A4 | ANDROGEN RECEPTOR MODULATORS AND METHODS OF USE THEREOF | MERCK & CO INC (US) | 2007-07-11 | — | — | EP | disclosed |
| EP-1420796-A1 | ANDROGEN RECEPTOR MODULATORS AND METHODS OF USE THEREOF | Merck & Co., Inc. (US) | 2004-05-26 | — | — | EP | disclosed |
| US-6645974-B2 | Administering an androstamide compound; osteoporosis, anticancer agents, glandular disorders | MERCK & CO., INC. | 2003-11-11 | — | — | US | disclosed |
| US-20030065004-A1 | Androgen receptor modulators and methods for use thereof | MERCK SHARP & DOHME CORP. | 2003-04-03 | — | — | US | disclosed |
| WO-2003011302-A1 | ANDROGEN RECEPTOR MODULATORS AND METHODS OF USE THEREOF | MERCK & CO., INC. (US) | 2003-02-13 | — | — | WO | disclosed |
| US-6432971-B2 | Method of prevention of prostatic carcinoma with 17β-N-monosubstituted-carbamoyl-4-aza-5α-androst-1-en-3-ones | MERCK & CO., INC. | 2002-08-13 | — | — | US | disclosed |
| US-20010049376-A1 | Method of prevention of prostatic carcinoma with 17beta-N-monosubstituted-carbamoyl-4-aza-5alpha-androst-1-en-3-ones | MERCK & CO., INC. | 2001-12-06 | — | — | US | disclosed |
| EP-0547691-B1 | The use of 17B-N-mono-substituted-carbamoyl-4-aza-5alpha-androst-1-en-3-ones for the preparation of a medicament for the prevention of prostatic carcinoma | MERCK & CO INC (US) | 1997-03-19 | — | — | EP | disclosed |
| EP-0674521-A1 | METHOD OF TREATMENT OF CHRONIC PROSTATITIS WITH 17$g(b)-N-MONOSUBSTITUTED-CARBAMOYL-4-AZA-5$g(a)-ANDROST-1-EN-3-ONES | MERCK & CO. INC. (US) | 1995-10-04 | — | — | EP | disclosed |
| WO-1994015602-A1 | COMBINATION METHOD FOR TREATING PATTERNED ALOPECIA WITH 17β-N-SUBSTITUTED-CARBAMOYL-4-AZA-5α-ANDROST-1-EN-3-ONES AND MINOXIDIL | MERCK & CO., INC. (US) | 1994-07-21 | — | — | WO | disclosed |
| WO-1994014452-A1 | METHOD OF TREATMENT OF CHRONIC PROSTATITIS WITH 17β-N-MONOSUBSTITUTED-CARBAMOYL-4-AZA-5α-ANDROST-1-EN-3-ONES | MERCK & CO., INC. (US) | 1994-07-07 | — | — | WO | disclosed |
| EP-0576603-A1 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF PROSTATIC HYPERPLASIA, CONTAINING A 5 ALPHA-REDUCTASE INHIBITOR AND AN ANTIANDROGEN | MERCK & CO. INC. (US) | 1994-01-05 | — | — | EP | disclosed |
| EP-0572166-A1 | New 7beta-substituted-4-aza-5a-androstan-3-ones as 5a-reductase inhibitors | MERCK & CO. INC. (US) | 1993-12-01 | — | — | EP | disclosed |
| EP-0547691-A1 | The use of 17B-N-mono-substituted-carbamoyl-4-aza-5alpha-androst-1-en-3-ones for the preparation of a medicament for the prevention of prostatic carcinoma | MERCK & CO. INC. (US) | 1993-06-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010049376-A1 | Method of prevention of prostatic carcinoma with 17beta-N-monosubstituted-carbamoyl-4-aza-5alpha-androst-1-en-3-ones | NR5A1, CYP17A1, HSD17B7 | AR 4/4885SRD5A2 11/4885KCNH2 3262/4885 |
| US-20030065004-A1 | Androgen receptor modulators and methods for use thereof | AR, FSHR, SHBG | AR 1/4885SRD5A2 80/4885KCNH2 4717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.